Similar articles for PMID: 30266781

Year	Number of Results
1933	5
1934	4
1985	1
1994	3
1995	1
2000	2
2001	1
2002	2
2003	5
2004	2
2005	1
2006	4
2007	2
2008	3
2009	2
2010	3
2011	3
2012	3
2014	1
2015	7
2016	6
2017	6
2018	14
2019	13
2020	3
2021	1
2022	2

1

Canadian status of "drugs to avoid" in 2017: a descriptive analysis.

Lexchin J. Lexchin J. CMAJ Open. 2018 Sep 28;6(3):E430-E435. doi: 10.9778/cmajo.20180049. Print 2018 Jul-Sep. CMAJ Open. 2018. PMID: 30266781 Free PMC article.

2

Health Canada's use of its priority review process for new drugs: a cohort study.

Lexchin J. Lexchin J. BMJ Open. 2015 May 11;5(5):e006816. doi: 10.1136/bmjopen-2014-006816. BMJ Open. 2015. PMID: 25967989 Free PMC article.

3

Formulary status of drugs in Ontario after Health Canada has issued a serious safety warning: a cohort study.

Lexchin J. Lexchin J. Int J Risk Saf Med. 2015;27(3):135-42. doi: 10.3233/JRS-150655. Int J Risk Saf Med. 2015. PMID: 26410247

4

How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study.

Lexchin J. Lexchin J. Healthc Policy. 2016 Nov;12(2):65-75. Healthc Policy. 2016. PMID: 28032825 Free PMC article.

5

A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers.

Foroutan N, Tarride JE, Xie F, Mills F, Levine M. Foroutan N, et al. Pharmacoecon Open. 2019 Dec;3(4):437-451. doi: 10.1007/s41669-019-0139-y. Pharmacoecon Open. 2019. PMID: 31041614 Free PMC article. Review.

6

Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis.

Lexchin J. Lexchin J. BMJ Open. 2017 Oct 22;7(10):e018372. doi: 10.1136/bmjopen-2017-018372. BMJ Open. 2017. PMID: 29061631 Free PMC article.

7

Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs in Canada? A Review of Submissions to the Canadian Agency for Drugs and Technologies in Health Common Drug Review.

Balijepalli C, Gullapalli L, Druyts E, Yan K, Desai K, Barakat S, Locklin J. Balijepalli C, et al. Clinicoecon Outcomes Res. 2020 Aug 24;12:445-457. doi: 10.2147/CEOR.S264589. eCollection 2020. Clinicoecon Outcomes Res. 2020. PMID: 32922050 Free PMC article. Review.

8

Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications.

Salek SM, Lussier Hoskyn S, Johns J, Allen N, Sehgal C. Salek SM, et al. Front Pharmacol. 2019 Feb 18;9:1578. doi: 10.3389/fphar.2018.01578. eCollection 2018. Front Pharmacol. 2019. PMID: 30833899 Free PMC article.

9

Stakeholders' feedback on the proposed recommendations for updating the patented medicine prices review board (pmprb) budget impact analysis guidelines.

Foroutan N, Tarride JE, Xie F, Jameel B, Mills F, Levine M. Foroutan N, et al. J Popul Ther Clin Pharmacol. 2020 Jan 3;27(1):e1-e24. doi: 10.15586/jptcp.v27i1.651. J Popul Ther Clin Pharmacol. 2020. PMID: 31922700

10

Marketing before patenting: implications for price controls in Canada.

Lexchin J. Lexchin J. Open Med. 2010;4(3):e139-42. Epub 2010 Jul 27. Open Med. 2010. PMID: 21687333 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed